Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

BACKGROUND: The aim of this study was to explore the relationship between follow-up imaging characteristics and overall survival (OS) in advanced hepatocellular carcinoma (HCC) patients under sorafenib treatment. METHODS: Associations between OS and objective response (OR) by mRECIST or early tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Öcal, Osman, Schinner, Regina, Schütte, Kerstin, de Toni, Enrico N., Loewe, Christian, van Delden, Otto, Vandecaveye, Vincent, Gebauer, Bernhard, Zech, Christoph J., Sengel, Christian, Bargellini, Irene, Gasbarrini, Antonio, Sangro, Bruno, Pech, Maciej, Malfertheiner, Peter, Ricke, Jens, Seidensticker, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725442/
https://www.ncbi.nlm.nih.gov/pubmed/34983668
http://dx.doi.org/10.1186/s40644-021-00439-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725442/
https://www.ncbi.nlm.nih.gov/pubmed/34983668
http://dx.doi.org/10.1186/s40644-021-00439-x

Ejemplares similares